Commercial Subunit vaccines are more useful for Lyme disease, directed to OspA, and the vaccine in humans was withdrawn in 2002 due to concerns raised by anti-vaccine groups regarding vaccine safety, vaccine cost, a difficult vaccination schedule and the potential need for boosters, class action lawsuits, uncertainty regarding risk of disease, and low public demand.